Karapetis, C.S., Khambata-Ford, S. and Jonker, D.J. (2008) KRAS Mutations and Benefit for Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359, 1747-1765.
http://dx.doi.org/10.1056/NEJMoa0804385

has been cited by the following article:

• TITLE: Case Report: Long-Term Survival in Patient with Cirrhosis of the Liver and Colon Cancer K-ras Wild-Type

  AUTHORS: Emiddio Barletta, Lucia Cannella, Vincenza Tinessa, Domenico Germano, Bruno Daniele

  KEYWORDS: K-ras Wild-Type Carcinoma, Metastatic Colorectal Cancer, Panitumumab, Anti-EGFR Treatment, Cirrhosis

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.3 No.6, June 24, 2014

  ABSTRACT: K-ras wild-type carcinoma is a tumour that is sensitive to treatment with anti-cancer and anti-EGFR drugs: the combination of Cetuximab and Panitumumab with chemotherapy (Cetuximab) or as a single therapy (Panitumumab). Case Report: The clinical case presented here refers to a 68-year-old patient who had been diagnosed with adenocarcinoma of the recto sigmoid with pelvic recurrence three years after surgery. The patient had a severe co-morbidity: correlated B-type liver cirrhosis. First-line chemotherapy was begun with Oxaliplatin plus Capecitabine (CAPOXI) following a relapse, and this continued for six months (six cycles), when the treatment was interrupted because of the disease’s progression and hematological and gastrointestinal toxicity. Following an assessment of the K-ras, diagnosed as wild type, the patient was excluded from second-line chemotherapy treatment because of decompensated cirrhosis and the persistence of thrombocytopenia and leukopenia. The patient was put forward for biological treatment with an anti-EGFR monoclonal antibody (Panitumumab). Panitumumab was administered at a dosage of 6 mg/kg every 2 weeks for 17 months; the treatment was well tolerated, despite the cirrhosis, and the main toxicity was the skin rash. Conclusion: In patients with severe comorbidities such as cirrhosis of the liver and K-ras wild-type carcinomas, therapy with a monoclonal antibody such as Panitumumab is a treatment that is well tolerated, with few serious toxic side-effects; it also offers advantages in terms of survival and clinical benefits.